Stay updated on Amivantamab & Lazertinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab & Lazertinib in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    No significant changes detected between the two screenshots; the study details, eligibility criteria, and outcomes remain unchanged.
    Difference
    0.4%
    Check dated 2025-11-03T20:37:33.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Publications now appear under the Publications section, including the Chen MF et al. article on amivantamab plus lazertinib (online ahead of print).
    Difference
    0.3%
    Check dated 2025-10-27T14:11:01.000Z thumbnail image
  3. Check
    30 days ago
    Change Detected
    Summary
    Added a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.
    Difference
    2%
    Check dated 2025-10-06T04:31:13.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    Upgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-29T01:19:13.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    Page revision updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed as a minor UI change.
    Difference
    0.1%
    Check dated 2025-09-14T18:48:01.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.1%
    Check dated 2025-09-07T13:13:59.000Z thumbnail image

Stay in the know with updates to Amivantamab & Lazertinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib in NSCLC Clinical Trial page.